NOW RECRUITING

May 2007
Dr. C. Douglas Witherspoon, M.D. serves as principal investigator for a clinical trial of a sugical device to restore vision & reduce visual symptoms eyes that have no lens & no iris due to injury or congenital defect.He will implant an artificial iris lens. The Ophtec Model 311 is an artificial iris that comes in brown, blue, or green and a full range of optical power.

Potential subjects for this study may contact Margaret Harrill by email or phone 1 800 292-8166 or 558-2533.

OPHTEC

artificial iris

 

Alcon Anecortave Acetate Risk Reduction Trial mid way in phase three clinical drug studies.

RECRUITMENT CLOSED
2006

In Birmingham, Dr. James Kimble will serve as principal investigator. He and Dr.Wayne Taylor at Retina Specialists of Alabama in Birmingham will join research physicians worldwide to enroll patients in the four year research study, which if successful, will add a heretofore unavailable preventative against complications of age related macular degeneration in the preservation of vision.

ALCON

Eye Research Activities of Retina Specialists of Alabama
Birmingham, Alabama

Dr. Robert Morris and Dr. C. Douglas Witherspoon are vitreoretinal surgeons whose practice, Retina Specialist of Alabama, LLC, is located in Birmingham, Alabama, U.S.A. They are faculty members in the University of Alabama at Birmingham Department of Ophthalmology, and clinical vision researchers for the Helen Keller Foundation for Research and Education.

Drs. Morris, Witherspoon, and Kuhn have contributed substantially to the development of effective and safe techniques for the surgical treatment of macular pucker, macular hole and the other traction maculopathies. In fact, they introduced the term traction maculopathy in 1994, calling attention to the common cause and treatment of these various disorders.

Their videotape productions of macular surgery, Key Hole and Apple Peel, and FILMS, repair of macular hole and macular pucker were selected "Best of Show," for excellence in the educational category at the annual meeting of the American Academy of Ophthalmology in 2000 and again in 2003. They were honored at ceremonies for this work.

After proving that the pathologic ILM can safely be removed from the macula, they developed a novel technique (FILMS™) to "float" the abnormal EMP/ILM complex from the macula. This patented technique (U.S. patent number 6,024,719, February, 2000) offers many advantages in that it is simple, fast, and easily reproducible. The ILM and all overlying proliferation is removed in one stage.

 

Patient Info|PFellowship Program |MaculaSurgery|
RSA Research
|RSA Physicians|RSA Location|Resources

Contact us at 205-933-2625 or 800-292-8166
Margaret Harrill - Web Master
-
rev. May 2007
This Site Contains Copyrighted Text And Graphics
© Copyright 2007 Retina Specialists of Alabama, LLC
Illustrations - ©
Steve Gordon